ZIVO · Zivo Bioscience, Inc. · Executive Compensation
$0.67
At close · Nov 27
Return incl. dividend (before tax)
Going-concern doubt
— flagged Nov 14, 2025
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company's ability to continue as a going concern within one year after the date the financial statements are issued.”View the 10-Q filed Nov 14, 2025
Market Cap
$16.53M
Shares
3.89M
Volume · Nov 27
226.8K
Avg daily vol (21 sessions)
42.21K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Andrew A. Dahl | Chief Executive Officer and Director | $2,960,134 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Andrew A. Dahl | Chief Executive Officer and Director | $240,000 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Alison A. Cornell | member of the Board of Directors | Resigned | 2026-03-30 |
| William A. Sullivan | Interim Chief Financial Officer | Resigned | 2026-03-30 |
| Keith R. Marchiando | Chief Financial Officer | Resigned | 2025-12-23 |
| Nola Masterson | member of the Board of Directors | Resigned | 2025-08-18 |
| Laith Yaldoo | Director | Appointed | 2024-07-17 |
Leadership
- John B. Payne CEO
- Keith Marchiando CFO
- Andrew A. Dahl Board Member
- Christopher D. Maggiore Board Member
- John B Board Member
- Keith R. Marchiando Board Member
- Laith Yaldoo Board Member
- Nola E Board Member